2022 AIM Physician and
Investigator Conference

May 21 – 22, 2022
Salt Lake City, Utah

Hosted by ARUP Laboratories

Overview

The American Initiative in Mast Cell Diseases (AIM) is pleased to announce the 2022 AIM Physician and Investigator Conference, taking place in Salt Lake City May 21-22, 2022. This conference will highlight scientific and clinical discoveries in mast cell disease, as well as clinical trials and newly developed national treatment guidelines. The program will include a roster of world-renowned speakers, a laboratory workshop, an engaging poster session, and opportunities to network. We anticipate more than 125 physicians and researchers to attend from around the world.

The 2022 conference will build upon the success of the inaugural event in 2019 at Stanford University and the second conference which was hosted virtually by ARUP Laboratories in Salt Lake City in May of 2021. As a result of these 2 conferences, AIM has established a network of more than 20 Reference Centers and Centers of Excellence for diagnostic and specialty care expertise.

Registration will be limited to physicians and researchers; there is no registration fee to attend.

Pharmaceutical representatives will have limited attendance, based on sponsorship. Please review opportunities to sponsor or exhibit at the conference.

AIM is committed to providing a safe and healthy atmosphere for our guests. The AIM Committee will be evaluating COVID-19 recommendations from the local, state, and federal health authorities and adjust safety measures or the meeting format as needed.

Schedule of Events

Friday, May 20, 2022
Laboratory Workshop and Conference Registration
Little America
11:00 – 12:00
Welcome
12:30 – 12:35
Serum tryptase testing: diagnostic and technical aspects
12:35 – 13:35

ARUP Laboratories and the University of Utah

Watch Now

Ultrasensitive quantitative KIT mutation testing in the diagnosis and monitoring of systemic mastocytosis
13:25 – 14:15

Kristin Karner, ARUP Laboratories and the University of Utah
Sabine Hellwig, ARUP Laboratories

Watch Now

Diagnostic and technical pitfalls in mast cell flow biology
14:51 – 15:00

David Ng, ARUP Laboratories and the University of Utah

Watch Now

Coffee Break
15:00 – 15:15
Role of immunohistochemistry in the diagnosis of mast cell disease
15:15 – 16:05

Olivia Tuiono, ARUP Laboratories

Watch Now

Bone marrow morphology in systemic mastocytosis: from quintessential to challenging
16:05 – 16:50

Anton Rets, ARUP Laboratories and the University of Utah

Watch Now

Closing remarks
16:50 – 17:00
Tour of ARUP Laboratories and Conference Registration at Little America
17:00 – 19:00

Shuttle departure from the Little America Lobby at 16:30

Welcome reception, Little America
Little America
19:00 – 20:30
Saturday, May 21, 2022
Registration and Breakfast
The Little America Hotel
7:30 – 8:10
Welcome/introductions
8:10 – 8:20
Diagnosis and Classification of Mast Cell Disorders: Joining The Master Class in Hematology
8:20 – 8:50

Professor Dr. Peter Valent, Medical University of Vienna

Q&A
8:50 – 9:00
Session 1: Research Updates in Mast Cell Biology
Chair: Lawrence Schwartz and Gunnar Nilsson
Substrates of Tryptase: Physiology and Pathology
9:00 – 9:20

Lawrence Schwartz, Virginia Commonwealth University

Watch Now

Role of mast cells in COVID-19 infection
9:20 – 9:40

Tina Schaller, University Medical Center Augsburg

Watch Now

Intraepithelial mast cell regulation and function
9:40 – 10:00

Dan Dwyer, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Update on Mast Cell Proteases
10:00 – 10:20

George Caughey, University of California at San Francisco

Watch Now

Hematopoietic origin of mast cells
10:20 – 10:40

Gunnar Nilsson, Karolinska Institute

Watch Now

Discussion Panel/Q&A
10:40 – 10:50
Coffee Break
10:50 – 11:10
Session 2: Classification, Pathology and Molecular Biology
Chairs: Michael Deininger and Olga Pozdnyakova
Myeloid gene mutations in advanced systemic mastocytosis
11:10 – 11:30

Michael Deininger, Medical College of Wisconsin

Watch Now

Screening for circulating tumor mast cells and molecular markers of systemic mastocytosis in blood.
11:30 – 11:50

Alberto Orfao, University of Salamanca CSIC-USAL

Histopathology changes during KIT inhibitor therapy
11:50 – 12:10

Tracy George, ARUP Laboratories and the University of Utah

Watch Now

GI pathology of mast cell disease
12:10 – 12:30

Jason Hornick, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Bone marrow and small intestinal manifestations of hereditary alpha tryptasemia
12:30 – 12:50

Olga Pozdnyakova, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Discussion Panel/Q&A
12:50 – 13:00
Lunch
13:00 – 14:00
Session 3: Mast Cell Activation and HaT
Chairs: Theo Gulen and Thanai Pongdee
MCAS Overview
14:00 – 14:20

Theo Gulen,  Karolinska University Hospital

Watch Now

The latest on hereditary alpha tryptasemia
14:20 – 14:40

Jonathan Lyons, National Institutes of Health

Cerebral blood flow in patients with hereditary alpha tryptasemia
14:40 – 15:00

Peter Novak, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Mast cell mediators in mastocytosis and HAT
15:00 – 15:20

Matt Giannetti, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

COVID-19 vaccine and other issues related to mast cell activation
15:20 – 15:40

Mariana Castells, Brigham and Women’s Mastocytosis Center, Harvard Medical School

Watch Now

Discussion Panel/Q&A
15:40 – 15:50
Poster Board Walk and Coffee Break (non-CME activity)
Ballroom C, 1st Floor
15:50 – 16:30

(non-CME activity)

Oral Presentations
16:30 – 17:10

Chairs: Pankit Vachhani and Prithviraj Bose

Anti-Siglec-6 Nanocarriers for the Targeted Delivery of Midostaurin to Mast Cells

Clayton Rische, Northwestern University

Watch Now

Targeted Next-Generation Sequencing Reveals Increased Prevalence of Somatic Myeloid Mutations in Pediatric Systemic Mastocytosis Compred to Pediatric Cutaneous Mastocytosis

Irina Maric, National Institutes of Health

Watch Now

Overall Survival, Duration of Treatment, and Reduction in Serum Tryptase Levels in Patients with Advanced Systemic Mastocytosis Treated with Avapritinib versus Best Available Therapy

Deepti Radia, Guy’s and St. Thomas’ Hospitals

Watch Now

Day 1 Closing Remarks
17:10
Sunday, May 22, 2022
Breakfast
Little America Hotel, Grand Ballroom 1st Floor
7:30 – 8:15
Special Session: Multidisciplinary interactive tumor board
8:15 – 9:30

Chairs: Jason Hornick and Deepti Radia

Olga Pozdnyakova, Brigham and Women’s Hospital, Harvard Medical School

Anton Rets, ARUP Laboratories and the University of Utah

Stephanie Lee, University of Toronto/St. Michael’s Hospital and Anne Tierens, Princess Margaret Cancer Centre

Watch Presentation 1

Watch Presentation 2

Session 4: Clinical Heterogeneity in Mast Cell Disease
Chairs: Matthew Hamilton
GI manifestations of mast cell disorders
9:30 – 9:50

Matthew Hamilton, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Pediatric Mastocytosis: A personalized approach to diagnosis and management
9:50 – 10:10

Melody Carter, National Institutes of Health

Osteoporosis in mast cell disease
10:10 – 10:30

Kamyar Asadipooya, University of Kentucky

Watch Now

Brain dysfunction in indolent systemic mastocytosis
10:30 – 10:50

Jennifer Nicoloro-SantaBarbara, Brigham and Women’s Hospital, Harvard Medical School

Watch Now

Cutaneous manifestations in mastocytosis: Update 2022
10:50 – 11:10

Karin Hartmann, University of Basel

Discussion Panel/Q&A
11:10 – 11:20
Coffee Break
11:20 – 11:40
Session 5: Therapies, novel agents and ECNM registry update
Chairs: Stephanie Lee and Tsewang Tashi
Indolent systemic mastocytosis
11:40 – 12:00

Cem Akin, University of Michigan

Advanced systemic mastocytosis
12:00 – 12:20

Deepti Radia, Guy’s and St. Thomas’ Hospitals

Watch Now

Retrospective comparisons of cladribine and midostaurin in advanced systemic mastocytosis
12:20 – 12:40

Andreas Reiter, University Hospital Mannheim, Heidelberg University

Update on the ECNM registry
12:40 – 13:00

Wolfgang Sperr, Medical University of Vienna

Watch Now

Future challenges and priorities in Mastocytosis
13:00 – 13:20

Jason Gotlib, Stanford University School of Medicine/Stanford Cancer Institute

Watch Now

Discussion Panel/Q&A
13:20 – 13:30
Lunch and Sponsor Lightning Round Presentations
13:30

(non-CME activity)

Session 6: Mast cell biology and pre-clinical development
Chairs: Melody Carter and Mariana Castells

(non-CME activity)

Bezuclastinib Selectivity to KIT A-loop Mutations, Minimal Brain Penetration, and Favorable Pharmacokinetic Properties in Preclinical Models
14:30 – 14:50

Alexandra Malinowski, Cogent Biosciences

Involvement and evaluation of KITD816V as a biomarker of avapritinib response in patients with Advanced SM
14:50 – 15:10

Mikael Rinne, Blueprint Medicines

Targeting Siglecs to Modulate Mast Cell Activity
15:10 – 15:30

Brad Youngblood, Allakos

Discussion Panel/Q&A
15:30 – 15:50
Day 2 Closing Remarks
15:50

(additional information forthcoming)

Accreditation: The University Of Utah School Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit: The University of Utah School of Medicine designates this Live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nondiscrimination and Disability Accommodation Statement: The University of Utah does not exclude, deny benefits to or otherwise discriminate against any person on the basis of race, color, national origin, sex, disability, age, veteran’s status, religion, gender identity/expression, genetic information, or sexual orientation in admission to or participation in its programs and activities. Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice. Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA, Title IX/Section 504/ADA Coordinator, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).

Speaker and Planning Committee Disclosure Summary

About the Area

Salt Lake City, Utah was selected as the venue for the AIM Conference as it is the home of ARUP Laboratories and the University of Utah. ARUP Laboratories, a nonprofit corporation affiliated with the University of Utah, is a leading reference laboratory in the United States and one of the few laboratories offering state-of-the-art testing for mast cell diseases. In addition, the university has an excellent reputation for cutting-edge basic research and translational science. Salt Lake City and the surrounding area is one of the fastest-growing areas in the United States featuring an international airport, a vibrant downtown with many restaurants and activities from which to choose, and several national parks within easy driving distance.

Sponsorship &
Exhibit Opportunities

Please join us in advancing research, treatment, and education related to mastocytosis and associated mast cell diseases.

The American Initiative in Mast Cell Diseases (AIM) is pleased to announce the 2022 AIM Physician and Investigator Conference. This conference will highlight scientific and clinical discoveries in mast cell disease, as well as clinical trials and newly developed national treatment guidelines. The program will include a roster of world-renowned speakers, a laboratory workshop, an engaging poster session, and opportunities to network. We anticipate the attendance of more than 125 physicians and researchers from around the world.

Our 2022 conference will build upon the success of the inaugural event in 2019 at Stanford University and the second conference, which was hosted virtually by ARUP Laboratories in Salt Lake City in May 2021. As a result of these two conferences, AIM has established a network of more than 20 Reference Centers and Centers of Excellence for diagnostic and specialty care expertise.

We invite you to become a conference sponsor. Please review the sponsorship opportunities and let us know if we can provide additional information or answer any questions. We are eager to partner with you to identify a sponsorship opportunity that aligns with your interests.

Please contact us for more information on sponsorship opportunities.

Sincerely,